Research Collaboration Index · 2026
Europe · Platinum standing
Strongest in Immunology & Microbiology, at #4 in the world.
The profile
By subject
World rank in each of the 26 subject indices; gold cards mark top-500 standings. Click through to any full subject ranking.
GRP Partnership Intelligence Platform
The peers you choose beside you across both GRP indices, the universities and companies your peers work with that you do not, live funding calls matched to your strengths and a brief ready for your executive. A partner service now onboarding founding partner universities: enquire, and the GRP team will confirm availability and pricing for your university.
Request first access for Université Paris Cité →
Independence. The index is free, public and independent; no commercial relationship changes any position. The platform, a partner service arranged with each university, reads the published record and cannot move a position.
Featured academics
Independently verified: current affiliation, public profile and published contact confirmed from the open record.
Borst directs the LaPsyDÉ laboratory and studies how children and adolescents develop reasoning, inhibitory control and resistance to fake news. A Fellow of the International Science Council, he works with schools across France to translate developmental cognitive neuroscience into classroom practice and evidence based education policy.
Cavazzana is a global pioneer of gene therapy who led the first successful treatments for severe combined immunodeficiency and sickle cell disease. Directing clinical investigation at Institut Imagine and Necker children's hospital, she coordinates international trials that have carried lentiviral therapies for blood disorders from bench to bedside.
Rieux-Laucat discovered key genetic causes of childhood autoimmunity, including FAS mutations behind autoimmune lymphoproliferative syndrome. His Institut Imagine laboratory maps how single gene defects break immune tolerance, and his multicentre collaborations on STAT3 and interferon autoantibodies are guiding targeted treatments such as JAK inhibitors for children with rare immune diseases.
Latest research news